Fig. 10.

Recombinant WISP-1 inhibits tumor growth and lung metastasis in mice. a Schematic of the experimental design. Where indicated, rWISP-1 (12.5 and 25 μg/kg) was intratumorally injected three times a week for 6 weeks starting 2 days after subcutaneous injection of 344SQ cells into syngeneic (129/Sν) mice (n = 8 mice per group). Mice were necropsied 6 weeks later. Scatter plots of body weight (b), primary tumor weight (d), tumor volume (e), and numbers of lung metastatic nodules (g). c Representative images of primary tumors (yellow dashed circles). f Representative images of lungs with and without metastases. The yellow dashed circles indicate lung metastatic nodules. NS: not significant, *P < 0.05, **P < 0.01, Kruskal‒Wallis test with Dunn’s post hoc test. The data are presented as the mean ± standard error of results from 8 mice per group (b, d, e, g). h Numbers of mice with (w/) and without (w/o) visibly determined metastases (Met). Phase contrast microscopy of migrated and invaded CD326⁺ tumor cells (i) and Thy1⁺ CAFs (j). Scale bars^: 100 µm. k Immunoblot analysis of proteins in CD326⁺ tumor cells. l qRT^‒PCR analysis of CAF markers and MMPs in isolated Thy1⁺ CAFs. NS: not significant, *P < 0.05, **P < 0.01, Kruskal‒Wallis test with Dunn’s post hoc test. The data are from three replicates per condition with cells pooled from two or three mice per replicate. The data are from one experiment representative of three independent experiments with similar results (i–k) or from three independent experiments (mean ± standard error; l)